
filo
Roche’s (RHHBY) Q3 financial results beat on the top line, though pharma sales just missed expectations.
Revenue of CHF16.13B ($19.61B) was a 7% year-over-year increase, beating the consensus of CHF15.75B ($19.15B).
Though pharma sales came in at $14.85B, that barely missed Street